HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent November 14, 2025 0 Cidara Therapeutics Provides Corporate Update and Reports Q3 2025 Results November 7, 2025 0 Knowing What Cidara Therapeutics is Doing for the Seasonal Flu October 28, 2025 0 BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 0